Goodwin advised ReNAgade Therapeutics on the fundraising. ReNAgade Therapeutics announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures. ReNAgade has...
ReNAgade Therapeutics’ $300 Million Series A Financing Round
ElevateBio’s $401 Million Series D Financing Round
Goodwin advised ElevateBio on the financing. ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by...
Blueprint Medicines Corporation’s Financing Collaborations with Sixth Street and Royalty Pharma
Goodwin Procter advised Blueprint Medicines Corporation on the deal while Cooley represented Sixth Street. Blueprint Medicines Corporation (NASDAQ: BPMC) announced its strategic financing collaborations with Sixth...
Janssen Pharmaceuticals’ Acquisition of Anakuria Therapeutics
Goodwin Procter advised Navitor Pharmaceuticals on the deal. Privately held Navitor Pharmaceuticals, LLC (“Navitor”), announced that Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies...
Adicet Bio’s $100.6 Million Rights Offering
Goodwin Procter advised Adicet Bio, Inc. on the deal. Adicet Bio, Inc. (Nasdaq: ACET) announced its underwritten public offering of 7,187,500 shares of its common stock, including...
Aura Biosciences’ $75.6 Million IPO
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
Laronde’s $440 Million Series B Financing
Goodwin Procter advised Laronde on the deal. Laronde announced its $440 million Series B Financing to advance the development of its eRNA platform and a broad pipeline...
Aerpio Pharmaceuticals’ Merger with Aadi Bioscience
Wilson Sonsini Goodrich & Rosati advised Aadi Bioscience on the deal while Goodwin Procter LLP represented Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals and Aadi Bioscience announced their...
Aura Biosciences’ $80 Million Financing Round
Goodwin Procter LLP advised Aura Biosciences on the deal. Aura Biosciences announced the closing of its oversubscribed $80 million financing. The financing was led by Matrix Capital...
ElevateBio’s $525 Million Series C Financing
Goodwin Procter LLP advised ElevateBio on the deal. ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced it...
Adicet Bio, Inc.’s $137.5 Million Rights Offering
Goodwin Procter LLP advised Adicet Bio, Inc. on the deal. Adicet Bio, Inc. (Nasdaq: ACET) announced its underwritten public offering of 10,575,513 shares of its common stock,...